Phase III FUTURE 1 study for Cosentyx shows continued impact on psoriatic arthritis at 5 years.- Novartis.

Novartis announced five-year data from the ongoing extensions of the phase III FUTURE 1 study for Cosentyx (secukinumab) in patients with psoriatic arthritis (PsA). In FUTURE 1, 83% and 94% of PsA patients achieved total resolution of enthesitis and dactylitis, respectively. Over 80% of patients who entered the extension phases of both studies completed five years. These data add to findings from the SCULPTURE study, in which two thirds of patients on Cosentyx reported no impact of skin disease on their quality of life over five years. Efficacy improved proportionately with dose escalation of Cosentyx to 150mg or 300mg during the study.

The safety profile of Cosentyx was shown to be consistent with that previously seen in clinical trials across multiple indications. A total of 460 patients entered a three-year extension period following the initial two-year study. Over 80% of patients who took part completed five years of Cosentyx treatment. These new data will be presented at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting.